The case for PCSK9 inhibitors is strong following the American College of Cardiology’s 67th annual symposium in Orlando, Florida, but some physicians remain wary of the medication, citing gaps in clinical evidence and questioning if cardiology is ready for the widespread distribution of such pricey drugs.